Quick Answer
Amphastar Pharmaceuticals, Inc. reported Stockholders Equity of $445.52 million for the year ending 2021.
- Amphastar Pharmaceuticals, Inc. showed an increase of +10.7% in Stockholders Equity from 2020 to 2021.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2022.
- XBRL data for this metric is available from 2011 to 2021 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: $287.74 million | Q3 2014: $283.12 million | Q1 2015: $279.28 million | Q2 2015: $285.27 million | Q3 2015: $283.79 million | Q1 2016: $296.59 million | Q2 2016: $307.46 million | Q3 2016: $328.45 million | Q1 2017: $325.56 million | Q2 2017: $333.31 million | Q3 2017: $330.66 million | Q1 2018: $327.10 million | Q2 2018: $320.53 million | Q3 2018: $319.42 million | Q1 2019: $334.99 million | Q2 2019: $387.85 million | Q3 2019: $389.41 million | Q1 2020: $377.51 million | Q2 2020: $397.68 million | Q3 2020: $450.96 million | Q1 2021: $405.56 million | Q2 2021: $421.99 million | Q3 2021: $430.18 million.
- Over the full 11 years of available data (2011 to 2021), Amphastar Pharmaceuticals, Inc.'s Stockholders Equity has grown by 113.7%.
- Historical annual values: Fiscal year 2021: $445.52 million | Fiscal year 2020: $402.31 million | Fiscal year 2019: $381.37 million | Fiscal year 2018: $332.44 million | Fiscal year 2017: $333.74 million | Fiscal year 2016: $329.26 million | Fiscal year 2015: $295.51 million | Fiscal year 2014: $281.86 million | Fiscal year 2013: $251.55 million | Fiscal year 2012: $233.44 million | Fiscal year 2011: $208.52 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: